Merck’s Suvorexant Driving Claims May Get Green Light After Lunesta Re-Label
This article was originally published in The Pink Sheet Daily
FDA signals comfort with declaring low dose of at least one insomnia product as OK for next-day driving, but suvorexant’s fate will depend on Merck’s data.
You may also be interested in...
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.